Treatment of hyperprolactinemias by pergolide mesylate
Loison, S.; Turpin, G.; Scherrer, H.; de Gennes, J.L.
Presse Medicale 16(28): 1377
1987
ISSN/ISBN: 0755-4982 PMID: 2957669 Document Number: 295604
Document emailed within 1 workday
Related Documents
Olanow, C.W.; Alberts, M.J. 1987: Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease Advances in Neurology 45: 555-560Scheinfeld, N. 2006: Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate Journal of Drugs in Dermatology: Jdd 5(3): 228-231
Fuller, R.W.; Clemens, J.A.; Hynes, M.D. 1982: Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia Journal of Clinical Psychopharmacology 2(6): 371-375
Landgraf, R.; Landgraf-Leurs, M.M.; von Werder, K.; Scriba, P.C. 1976: Therapy of the diabetic metabolic condition in hyperprolactinemias and acromegaly Verhandlungen der Deutschen Gesellschaft für Innere Medizin 82 Pt 2: 1915-1917
Bar-Sela, G.; Lev, L.M.; Kuten, A.; Wollner, M.; Haim, N. 2006: Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients Harefuah 145(1): 2-7 80
Ritter, M.M.; Richter, W.O.; Schwandt, P. 1992: Metabolic consequences of long-term antihypertensive treatment with co-dergocrine mesylate/nifedipine in high age groups Arzneimittel-Forschung 42(3): 311-313
Kitamura, S. 1980: The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine') Pharmatherapeutica 2(5): 330-336
Login, I.S. 1984: Pergolide versus bromocriptine Neurology 34(2): 258
Neshige, R. 2005: Optimum dosage of pergolide in patients with Parkinson's disease Rinsho Shinkeigaku 45(4): 328-330
Toyokawa, T.; Teraoka, H.; Kitayama, K.; Nomura, S.; Kanehara, I.; Nishino, H. 2014: A case report of two-term surgery for focal progression of a huge liver metastasis and peritoneal dissemination from gastrointestinal stromal tumor during imatinib mesylate treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(3): 373-377
Gordon, J.; Udeh, U.; Doobay, K.; Magro, C.; Wildman, H.; Davids, M.; Mersten, J.N.; Huang, W.-T.; Lyman, S.; Crow, M.K.; Spiera, R.F. 2014: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial Clinical and Experimental Rheumatology 32(6 Suppl 86: S
Bilici, A.; Karadag, B.; Doventas, A.; Erdincler, D.S.; Cetinkaya, S.; Ogut, G.; Tezcan, V.; Beger, T. 2004: Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease Netherlands Journal of Medicine 62(10): 389-392
Fuller, R.W.; Snoddy, H.D. 1982: Serum corticosterone elevation by pergolide in rats: prevention of tolerance development by spiperone Journal of Pharmacy and Pharmacology 34(9): 607-608
Asanuma, M.; Ogawa, N.; Nishibayashi, S.; Kawai, M.; Kondo, Y.; Iwata, E. 1995: Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain Archives Internationales de Pharmacodynamie et de Therapie 329(2): 221-230
Cavero, I.; Lorrain, J.; Di Paola, E.D.; Lhoste, F.; Payen, B.; Dennis, T.; Scatton, B. 1985: Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs Journal of Pharmacology and Experimental Therapeutics 235(3): 798-809
Heinzl, S. 2002: The tyrosine kinase antagonist imatinib mesylate Medizinische Monatsschrift für Pharmazeuten 25(1): 4-7
Zorgniotti, A.W. 1994: Experience with buccal phentolamine mesylate for impotence International Journal of Impotence Research 6(1): 37-41
Zhu, J.-h.; Li, Q.-w.; Xiao, W.-h.; Sun, J.-z.; Wang, R.-l.; Lu, J.-y. 2011: Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate Zhonghua Zhong Liu Za Zhi 33(6): 470-472
Fukawa, K.; Honda, H.; Kubota, H.; Hatanaka, Y.; Sawabe, T. 1982: Effects of dihydroergotamine mesylate (DEM) on the cardiovascular and nervous systems Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 79(3): 225-236
Xu, J.-q.; Zhu, B.; Ye, T.-h. 2005: Clinical effects of ropivacaine mesylate in epidural anesthesia and analgesia Chinese Medical Sciences Journal 20(1): 70-73